9 Most Undervalued Pharma Stocks to Buy Right Now

6. Lantheus Holdings, Inc. (NASDAQ:LNTH)

Forward P/E Ratio: 11.04

Price Target Upside: 17.83%

Lantheus Holdings, Inc. (NASDAQ:LNTH) is among the most undervalued stocks.

On December 11, TheFly reported that Truist Securities upgraded LNTH from Hold to Buy and raised its price target to $80, reflecting a more optimistic view of the company’s growth prospects and belief that the current valuation underrates future revenue and earnings potential.

The upgrade reflected expected profit re-acceleration into late 2025 and beyond and was supported by LNTH’s strong financial performance and strategic positioning relative to industry peers.

This positive view is connected to Lantheus Holdings, Inc. (NASDAQ:LNTH)’s third-quarter 2025 results released on November 6th, in which the company reported $384 million in revenue, adjusted EPS of $1.27, and $94.7 million in free cash flow, despite some pressure on its core PYLARIFY franchise.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company dedicated to providing innovative diagnostic and therapeutic products to improve patient outcomes.